ReviewMolecular biotechnology2021
Novel Strategies to Combat Bacterial Biofilms.
Review in Molecular biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Understanding bacterial biofilms: From definition to treatment strategies.Frontiers in cellular and infection microbiology · 2023Pooled it
- Comparative Evaluation of the Effects of Agar and Biofilm Cultures of Francisella tularensis on the Immunological Reactivity of Experimental Animals.Bulletin of experimental biology and medicine · 2026Article
- Targeting biofilm-driven antibiotic resistance: emerging mechanisms and next-generation therapeutic interventions.Frontiers in microbiology · 2026Review
- Review
- Trifunctional synergistically designed 3D-Printed bone scaffold for infectious bone defect therapy: design strategy and clinical translation outlook.Frontiers in bioengineering and biotechnology · 2026Review
- Biofilm Formation on Indwelling Medical Devices: A Review of Health and Economic Implications.International journal of microbiology · 2026Review
- Resistance breakers: a novel approach to tackle biofilm associated infections and antimicrobial resistance.Frontiers in microbiology · 2026Review
- Modern therapeutic strategies to mitigate biofilm-associated infection in livestock organisms.Antonie van Leeuwenhoek · 2025Review
- Interference ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Article
- Antimicrobial Peptides: A Promising Alternative to Conventional Antimicrobials for Combating Polymicrobial Biofilms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Isolation and Characterization of Three Lytic Bacteriophages to Overcome Multidrug-, Extensive Drug-, and Pandrug-ResistantPHAGE (New Rochelle, N.Y.) · 2024Article
- Inhibition ofmSphere · 2024Article
- A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.Molecular biology reports · 2024Review
- Lactoferrin Affects the Viability of Bacteria in a Biofilm and the Formation of a New Biofilm Cycle ofInternational journal of molecular sciences · 2024Article
- Anti-Biofilm Effects of Z102-E ofFoods (Basel, Switzerland) · 2024Article
- Article
- Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: a key to advancing biofilm-targeted therapeutic strategies.Archives of microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilms are considered as a severe problem in the treatment of bacterial infections; their development causes some noticeable resistance to antibacterial agents. Biofilms are responsible for at least two-thirds of all infections, displaying promoted resistance to classical antibiotic treatments. Therefore, finding new alternative therapeutic approaches is essential for the treatment and inhibition of biofilm-related infections. Therefore, this review aims to describe the potential therapeutic strategies that can inhibit bacterial biofilm development; these include the usage of antiadhesion agents, AMPs, bacteriophages, QSIs, aptamers, NPs and PNAs, which can prevent or eradicate the formation of biofilms. These antibiofilm agents represent a promising therapeutic target in the treatment of biofilm infections and development of a strong capability to interfere with different phases of the biofilm development, including adherence, polysaccharide intercellular adhesion (PIA), quorum sensing molecules and cell-to-cell connection, bacterial aggregation, planktonic bacteria killing and host-immune response modulation. In addition, these components, in combination with antibiotics, can lead to the development of some kind of powerful combined therapy against bacterial biofilm-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.